CD6 and myeloid sarcoma: These intriguing results suggest that the CD6-ADC holds promise as a drug for treating pathogenic T cell–mediated disorders, including but not limited to diseases like autoimmune uveitis, MS, RA, GVHD, and transplantation rejections.